For more than four decades, comedian Jerry Lewis hosted the MDA Labor Day Telethon on behalf of the Muscular Dystrophy Association. That annual event helped the MDA become the nation’s largest non-government source of funding for neuromuscular disease research, with more than $1.4 billion disbursed since its establishment 68…
News
A gene therapy strategy to treat Charcot-Marie-Tooth disease 4 subtype C (CMT4C), targeted to correct the myelin-producing cells of the peripheral nervous system, showed positive results in a mouse model. The data provide proof-of-principle support for gene therapy to treat CMT4C and potentially other similar demyelinating inherited nerve diseases.
Increasing levels of the mitofusin-1 (MFN1) protein in nerve cells of the spinal cord can reverse the features of Charcot-Marie-Tooth type 2A (CMT2A), a study in mice shows. The study, “Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A…
An imaging technique called 3D multiple gradient echo Dixon-based MRI may be a highly reliable and more sensitive tool for evaluating muscle degeneration in people with Charcot-Marie-Tooth (CMT) disease, a study reports. This technology enables the mapping and quantification of the proportion of fat within…
Several Charcot-Marie-Tooth Association (CMTA) events are planned in the coming months for Charcot-Marie-Tooth (CMT) patients and caregivers. The organization is hosting a live Facebook webinar March 26 at 9 p.m. EDT. It will feature Kate Lair, a member of the CMTA advisory board and former claims adjudicator. The…
A new study reports a mutation in the gene EGR2 that caused Charcot-Marie-Tooth disease type 2 (CMT2) in an Italian family. The study, “A novel family with axonal Charcot-Marie-Tooth disease caused by a mutation in the EGR2 gene,” was published in Journal of the Peripheral Nervous System. The…
Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bath dissertation, she analyzed Brexit’s long-term impact…
With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,” warned Avraham Steinberg,…
A research project that is now underway and recruiting participants is intended to identify new disease-causing genetic mutations in Charcot-Marie-Tooth (CMT) disease patients. The goal of the observational trial (NCT01193088), known as INC-6602, is to identify new genes that cause CMT, namely CMT type 2, and genes…
ACE-083 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) to treat Charcot-Marie-Tooth (CMT) disease, the therapy’s developer Acceleron Pharma announced. The treatment is being tested in 15 U.S. states in a Phase 2 trial (NCT03124459) that is enrolling participants with …
Recent Posts
- Novel gene therapy for CMT4C shows proof of principle in treating mice
- A scientist’s perspective on the landscape of CMT research
- Renowned European geneticist bringing expertise to CMTA as new adviser
- Finding productive ways to channel my frustration with CMT
- Raising awareness of the hidden costs of Charcot-Marie-Tooth disease